Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

55X_ROI_Q1_2026 Aug. 25 at 8:24 PM

$SLS See the forest through the trees... all this trading is irrelevant - and will be forgotten instantly when the Phase 3 Results are announced... Gps is worth $50 Per Share to $MRK or $BMY JUST FOR Ovarian Cancer https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won

0 · Reply

Jwa68 Aug. 25 at 7:06 PM

$COYA Seems l like things are all falling in place for DRL. COYA 302 becomes more and more real for them by the day, especially with todays news. $BMY $XBI This is India approved not US, but it is a hell of a step in the right direction! https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/dr-reddys-wins-marketing-approval-for-abatacept-biosimilar-in-india/133513131

0 · Reply

Trading4Living Aug. 25 at 3:48 PM

$BMY beauty

0 · Reply

Reanimated666 Aug. 25 at 3:27 PM

$BMY Looks primed to breakout

0 · Reply

ajbski Aug. 25 at 2:54 PM

$NVAX 🚨Novavax unnamed partner for the immuno-oncology MTA is a "top-10 global pharmaceutical company and global oncology leader." Industry analysts identify the most likely candidate as: 1) Merck & Co. $MRK 2) AstraZeneca $AZN 3) Roche/Genentech $RHHBY 4) Bristol Myers Squibb $BMY https://share.google/aimode/lR4vGA4S3vSo6P42t

1 · Reply

STOCKPICKERTRADER Aug. 25 at 2:36 PM

$BMY remember when that Fool Clown Cramer was on CNBC saying these guys had no pipeline and to stay away when price was 40... idiot also said same thing about oil when it was 20/bbl.... and $MRK when it was in the 70's.... Hmmm

0 · Reply

USAEquityResearch Aug. 25 at 11:47 AM

$BMY 📊 USAEquityResearch ▲ 67.28 (+0.40%) Trend: Bullish 📈 RSI (14): 54.9 — neutral territory MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 67.61 | Support: 63.10 20-MA: 64.97 | 50-MA: 60.61 💼 Fundamentals Mkt Cap: $137.43B P/E (TTM): 14.8 | Fwd P/E: 10.3 FCF: $8.11B (3.97/sh) Total Debt: $45.05B D/E: 201.86 📉 Options (exp 2026-08-28) ATM IV: 0.8% | Skew: +0.0% (balanced) P/C Ratio: 0.98 ⚖️ Neutral Max Pain: 65.00 Call wall: 68.00 | Put wall: 67.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/BMY

0 · Reply

viggizags Aug. 25 at 8:20 AM

$SPY i said yesterday that boring is exciting, some of the most boring stocks have really nice charts $GIS $KMB $KO $BMY I have some others but boy does that stuff look good plus others in staples and the drug stocks

0 · Reply

Quantumup Aug. 24 at 11:32 AM

H.C. Wainwright⬆️ $LBRX's PT to $60,⬆️PoA, reiterated Buy and said -- LB Pharmaceuticals' lead asset, LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders. $BMY $MPLT ABBV PRAX TEVA NMRA VNDA SNY XENE BHVN RAPP Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2091851044753940939?s=20

0 · Reply

Quantumup Aug. 24 at 10:22 AM

Citizens reiterated $KURA at Market Outperform-$24 after Kura recently announced 2Q26 financial results. $SNDX $BMY AMGN ABBV - RHHBY Citizens said -- With the KOMZIFTI launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform expected to enter registrational studies in 2028, and a cash position of $519MM, we believe Kura shares represent an attractive investment, with ~57% potential downside (bear case of $5) and ~156% potential upside (bull case of $30).

0 · Reply

Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner

Aug 25, 2026, 12:58 PM EDT - 8 hours ago

Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares

Aug 20, 2026, 9:00 AM EDT - 5 days ago

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

Aug 19, 2026, 5:30 AM EDT - 6 days ago

Market Cap	130.39B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.93
Forward PE	9.28
Profit Margin	14.64%
Debt to Equity Ratio	1.93

Volume	7,529,800
Avg Vol	12,444,174
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	25%
Beta	0.22
Analysts	Sell
Price Target	$66.30